Comprehensive genomic profiling for cancer

Decoding the differences of cancer at a genomic level is key to precision oncology. Agilent Technologies introduces the SureSelect Cancer Comprehensive Genomic Profiling Assay. Using NGS, this technology enables you to detect potential biomarkers from solid tumors by profiling clinically relevant genes and assessing key classes of mutations to gain molecular insights into tumors.